1. Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Disease-Modifying Treatments for MS

5. Evolving Therapeutic Landscape in MS

6. Maintenance/Escalation Therapy vs IRT

7. Predictors of Disability Disease Factors

8. Predictors of Disability Patient Factors

9. Predictors of Disability: Imaging

10. Neurofilament Levels as Markers of Disease Activity

11. Benefit of Early Treatment Initiation

12. Monitoring Burden With DMT

13. Case Study 1

14. Case Study 1 Workup

15. Case Study 1: Treatment Considerations

16. Pregnancy Considerations With DMT Use

17. Reduced Risk of CIS Conversion to CDMS With Cladribine

18. Case Study 2

19. Case Study 2 MRI Findings

20. Case Study 2 Treatment Considerations

21. Case Study 3

22. Case Study 3 Workup Postpartum

23. Case Study 3 Treatment Considerations

24. Case Study 3 Potential Role for IVIG?

25. Conclusions

26. Abbreviations

27. Abbreviations (cont)

28. Abbreviations (cont)